ONO Pharmaceutical
International pharmaceutical company focused on discovery and development of original prescription drugs with strategic emphasis on oncology, immunology, neurology and specialty areas. Operates integrated R&D, GMP-compliant manufacturing, global clinical development and commercialization activities, and is expanding digital and data capabilities to support research, safety monitoring and information dissemination.
Industries
Nr. of Employees
Very Large (1000+)
ONO Pharmaceutical
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan
Patents
Salt and crystal form of compound having agonistic activity to S1P5 receptor
US-12459890-B2
View Details
Salt and crystal form of compound having agonistic activity to S1P5 receptor
US-12459890-B2
View DetailsProducts
Marketed PD-1 immune checkpoint inhibitor (monoclonal antibody)
A marketed human anti‑PD‑1 monoclonal antibody developed for the treatment of multiple tumor types (first approved PD‑1 inhibitor referenced in company history).
Oncology small molecules and biologics pipeline
Multiple oncology development-stage candidates including small molecules and biologics acquired or developed in-house to expand therapeutic options.
iPS-derived CAR-T clinical candidate (entered clinical trials 2024)
Cell therapy candidate derived from iPS cells and engineered with chimeric antigen receptors (CAR-T) developed through collaboration with an external iPS-CAR-T specialist; advanced to clinical trials in 2024.
Marketed PD-1 immune checkpoint inhibitor (monoclonal antibody)
A marketed human anti‑PD‑1 monoclonal antibody developed for the treatment of multiple tumor types (first approved PD‑1 inhibitor referenced in company history).
Oncology small molecules and biologics pipeline
Multiple oncology development-stage candidates including small molecules and biologics acquired or developed in-house to expand therapeutic options.
iPS-derived CAR-T clinical candidate (entered clinical trials 2024)
Cell therapy candidate derived from iPS cells and engineered with chimeric antigen receptors (CAR-T) developed through collaboration with an external iPS-CAR-T specialist; advanced to clinical trials in 2024.
Services
In-house discovery programs and collaborative R&D with academic and industry partners to identify and advance therapeutic candidates.
Commercial manufacturing at GMP-compliant sites and management of contract manufacturing partners through audits, quality agreements and supplier controls.
Clinical trial design and execution capabilities with regional clinical development centers and regulatory filing support for multi-region submissions.
Development and use of enterprise data platforms and digital tools for data analysis, digital transformation initiatives, and patient/healthcare professional engagement.
Provision of scientific information to healthcare professionals via omnichannel approaches, online seminars, symposiums and regionally targeted activities.
In-house discovery programs and collaborative R&D with academic and industry partners to identify and advance therapeutic candidates.
Commercial manufacturing at GMP-compliant sites and management of contract manufacturing partners through audits, quality agreements and supplier controls.
Clinical trial design and execution capabilities with regional clinical development centers and regulatory filing support for multi-region submissions.
Development and use of enterprise data platforms and digital tools for data analysis, digital transformation initiatives, and patient/healthcare professional engagement.
Provision of scientific information to healthcare professionals via omnichannel approaches, online seminars, symposiums and regionally targeted activities.
Expertise Areas
- Immuno-oncology research and development
- Antibody and cell therapy development
- iPS-derived CAR-T development
- Small-molecule drug discovery
Key Technologies
- Antibody therapeutics
- Cell therapy platforms
- iPS-derived CAR-T
- Immuno-oncology modalities
News & Updates
Company history records the authorization and market launch in 2014 of the first human anti‑PD‑1 monoclonal antibody referenced by the company.
Acquisition completed in June 2024 to enhance oncology R&D and commercial capabilities in the U.S. and Europe.
A collaborative program with an external iPS-CAR-T developer produced a cell therapy candidate that proceeded to clinical trials in 2024.
Company history records the authorization and market launch in 2014 of the first human anti‑PD‑1 monoclonal antibody referenced by the company.
Acquisition completed in June 2024 to enhance oncology R&D and commercial capabilities in the U.S. and Europe.
A collaborative program with an external iPS-CAR-T developer produced a cell therapy candidate that proceeded to clinical trials in 2024.